Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National Institute for Health
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine Interventional procedures guidance Published: 26 October 2022 www.nice.org.uk/guidance/ipg740 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the supraorbital nerve for treating and preventing migraine is adequate and raises no major safety concerns. For efficacy: • The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research
Atogepant (Qulipta) - For the prevention of migraine in adults who have at least 4 migraine days per month View of Atogepant (Qulipta) | Canadian Journal of Health TechnologiesReturn to Article DetailsAtogepant (Qulipta)
IV Steroids for Prevention of Rebound Migraine Headache IV Steroids for Prevention of Rebound Migraine Headache - Emergency MedicineSkip to contentSkip to searchSkip to footerWashington University School of Medicine in St. LouisEmergency MedicineOpen MenuBackCloseMenuSearch for:SearchClose Search * WelcomeWelcome * Mission * Clinical Sites * Explore St. Louis * Our TeamOur Team Magnesium for Acute COPD Exacerbations * Publications * Vanc/Zosyn and Kidney Injury * IV Steroids for Prevention of Rebound Migraine HeadacheOpen Search IV Steroids for Prevention of Rebound Migraine HeadacheWashington University Emergency Medicine Journal Club- January 2024VignetteYou are moonlighting in your community ED one weekday afternoon when youencounter Ms. M, a 37-year-old woman with a history
Migraine headache in adults Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageMigraine headache in adults MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:17 Apr 2023Last updated:26 Apr 2023SummaryMigraine is a chronic, episodic, neurological disorder that has a strong genetic component and usually presents in early-to-mid life. It can have a severe effect on quality of life, but it is often under-diagnosed and under-treated.Patients complain of intermittent headache and associated symptoms, such as visual disturbance, nausea, vomiting, and sensitivity to light or noise (photophobia and phonophobia).Some women experience menstrual migraine, which is most likely to occur in the 2 days
Migraine headache in children Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageMigraine headache in children MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:30 Jul 2023Last updated:24 Aug 2023SummaryMigraine has a high prevalence in children (10%) and is a significant source in over 12s: diagnosis and managementPractice guideline update: pharmacologic treatment for pediatric migraine preventionMore GuidelinesPatient leafletsMigraine in childrenMigraine in children: medicines to prevent attacksMore Patient leafletsLog in or subscribe to access all of BMJ Best PracticeUse of this content is subject to our disclaimerLog in or subscribe to access all of BMJ Best PracticeSEE ALL
Pharmacological management of migraine Pharmacological management of migraineA national clinical guidelineFirst published February 2018Revised September 2022SIGN155Key to evidence statements and recommendationsLevels of evidence1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias1+ Well-conducted meta-analyses, systematic reviews, or RCTs Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2022. (SIGN publication no. 155). [February 2022]. Available from URL: http://www.sign.ac.ukThis document is licensed under the Creative Commons Attribution-Noncommercial-NoDerivatives 4.0 International Licence. This allows for the copy and redistribution of this document as long as SIGN is fully acknowledged and given
Pharmacological management of migraine SIGN 155 • Pharmacological management of migraineA national clinical guideline February 2018 Evidencewww.healthcareimprovementscotland.orgEdinburgh Office | Gyle Square |1 South Gyle Crescent | Edinburgh | EH12 9EB Telephone 0131 623 4300 Fax 0131 623 4299Glasgow Office | Delta House | 50 West Nile Street | Glasgow | G1 978 1 909103 62 7Citation textScottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of migraine. Edinburgh: SIGN; 2018. (SIGN publication no. 155). [February 2018]. Available from URL: http://www.sign.ac.ukSIGN consents to the photocopying of this guideline for the purpose of implementation in NHSScotland.Pharmacological management of migraineContents1
Lasmiditan (migraine) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 4 of the dossier assessment Lasmiditan (Migräne) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding . Lasmiditan (migraine) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-35 Version: 1.0 Status: 22 June 2023 Extract of dossier assessment A23-35 Version 1.0 Lasmiditan ( migraine) 22 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Lasmiditan (migraine) – Benefit assessment
Atogepant (Qulipta) - Migraine, prevention View of Atogepant (Qulipta) | Canadian Journal of Health Technologies Return to Article DetailsAtogepant (Qulipta)
Which drugs are best for migraine attacks? Which drugs are best for migraine attacks?Which drugs are best for migraine attacks?Skip to content * Accessibility options: * * Search articles Evidence * About us * Browse content * Brain and Nerves * Birth Conditions * Blood * Cancer * Dementia * Detection, Screening and Diagnosis * Diabetes, Metabolics and Hormones * Diet, Obesity and Nutrition * Ear are best for migraine attacks? Which drugs are best for migraine attacks?Brain and Nerves 04.03.25 doi: 10.3310/nihrevidence_66054 View commentaries and related content This is a plain English summary of an original research article. The views expressed are those of the author(s) and reviewer(s) at the time of publication. Researchers ranked oral treatments for migraine attacks in an analysis of 137
Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians 1 3 14 The American College of Physicians (ACP) developed this clinical guideline for clinicians caring adults with episodic migraine headache (defined as to days per month) in outpatient settings. ACP based these recommendations on systematic reviews the comparative benefits and harms pharmacologic treatments prevent migraine, patients' values preferences, economic evidence. evaluated effectiveness following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan telmisartan), antiseizure medications (valproate topiramate), β-blockers (metoprolol propranolol), calcitonin
Zavegepant (Zavzpret) - migraine Skip to main contentSkip to FDA SearchSkip to footer links An official website of the United States government Here's how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search Home Drugs Drug Approvals and Databases Drugs@FDADrug Approval Package: ZAVZPRETShareTweetLinkedinEmailPrintCompany: Pfizer Inc.Application Number: 216386Approval
Ubrogepant (Ubrelvy) - acute treatment of migraine Skip to main contentSkip to "About this site"Basic HTML versionGovernment of CanadaSearch and menusSearch and menusYou are here:HomeAll ServicesHealthDrugs, health & consumer productsReview DecisionsSummary Basis of Decision - Ubrelvy - Health CanadaDrugsNatural Health ProductsMedical DevicesReview Decisions Submit a report Prescription Drug -uncertainty profile of Ubrelvy is favourable for the acute treatment of migraine with or without aura in adults.1 What was approved?2 Why was Ubrelvy approved?3 What steps led to the approval of Ubrelvy?4 What follow-up measures will the company take?5 What post-authorization activity has taken place for Ubrelvy?6 What other information is available about drugs?7 What was the scientific rationale for Health